May 20, 2020
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Jun 18, 2019
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
May 23, 2019
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
May 07, 2019
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
Mar 25, 2019
Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
Feb 19, 2019
Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
Jan 28, 2019
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Jan 23, 2019
Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
Nov 12, 2018
Michael J. Fox Foundation Honors Virginia Man-Yee Lee, PhD, with Robert A. Pritzker Prize for Leadership in Parkinson's Research
Sep 05, 2018
Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy
Aug 01, 2018
Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
May 17, 2018
Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
Dec 05, 2017
ICBII Announces the Filing of Orphan Drug Designation Application for the Use of a-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy
Oct 24, 2017
Michael J. Fox Foundation and Tau Consortium Announce Partnership to Develop New Imaging Tools for Devastating Neurodegenerative Diseases
Jun 07, 2017
AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE® PD03A, Confirming Immunogenicity and Safety Profile in Parkinson's Disease Patients